Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

References

• The Global Asthma Report 2014. Auckland, New Zealand: Global Asthma Network; 2014. Available at: http://www.globalasthmareport.org/. Accessed August 3, 2017
   Google Scholar
• ERS. Adult asthma. European Lung White Book; updated March 2017. Available at: http://www.erswhitebook.org/chapters/adult-asthma/. Accessed August 3, 2017
   Google Scholar
• CDC. National - Current Asthma Prevalence (2015); 2017 [updated June 2017]. Available at: https://www.cdc.gov/asthma/most_recent_data.htm. Accessed August 3, 2017
   Google Scholar
• Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 2011;242:10-30
   PubMed Web of Science ®Google Scholar
• Lombardi C, Savi E, Ridolo E, et al. Is allergic sensitization relevant in severe asthma? Which allergens may be culprit? W Allergy Org J 2017;10:2
   PubMed Web of Science ®Google Scholar
• XOLAIR (omalizumab) [Prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016
   Google Scholar
• XOLAIR Summary of product characteristics. Nuremberg, Germany: Novartis Pharma GmbH; 2016
   Google Scholar
• FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. FDA; 2009 Available at: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed August 3, 2017
   Google Scholar
• Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights 2013;6:61-8
   PubMedGoogle Scholar
• Gibbons E, Fitzpatrick R. A structured review of patient-reported outcome measures (PROMs) for asthma. University of Oxford; 2009 Available at: http://phi.uhce.ox.ac.uk/pdf/PROMs_Oxford_Asthma_17092010.pdf. Accessed August 3, 2017
   Google Scholar
• Worth A, Hammersley V, Knibb R, et al. Patient-reported outcome measures for asthma: a systematic review. NPJ Primary Care Resp Med 2014;24:14020
   PubMed Web of Science ®Google Scholar
• Frampton GK, Shepherd J. Patient-reported outcomes in clinical trials of inhaled asthma medications: systematic review and research needs. Qual Life Res Int J Qual Life Aspects Treat Care Rehab 2011;20:343-57
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671-8
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Resp J 2002;20:1088-94
   PubMed Web of Science ®Google Scholar
• Humbert M, Berger W, Rapatz G, et al. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 2008;63:592-6
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-16
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Resp Med 2008;102:1371-8
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Archives Allergy Immunol 2003;131:46-52
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Resp J 2001;18:254-61
   PubMed Web of Science ®Google Scholar
• Bardelas J, Figliomeni M, Kianifard F, et al. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma Offic J Assoc Care Asthma 2012;49:144-52
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278-84
   PubMed Web of Science ®Google Scholar
• Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64:81-4
   PubMed Web of Science ®Google Scholar
• Rubin AS, Souza-Machado A, Andradre-Lima M, et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma Offic J Assoc Care Asthma 2012;49:288-93
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
   PubMed Web of Science ®Google Scholar
• Chanez P, Contin-Bordes C, Garcia G, et al. Omalizumab-induced decrease of FcxiRI expression in patients with severe allergic asthma. Resp Med 2010;104:1608-17
   PubMed Web of Science ®Google Scholar
• Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011;127:398-405
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Resp Int Rev Thorac Dis 2012;83:520-8
   Google Scholar
• Ohta K, Miyamoto T, Amagasaki T, et al. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology (Carlton, Vic) 2009;14:1156-65
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-15
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015;136:1476-85
   PubMed Web of Science ®Google Scholar
• Andreasson E, Svensson K, Beerggren F. Validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): results from a web-based study [PRP11]. Value Health 2003;6:780
   Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life questionnaire. J Clin Epidemiol 1994;47:81-7
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol 2004;34:632-8
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110:e55
   PubMed Web of Science ®Google Scholar
• Vermeulen F, de Meulder I, Paesmans M, et al. Asthma control measurement using five different questionnaires: a prospective study. Resp Med 2013;107:1314-21
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Gold K, Schulman KA, et al. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 1997;100:16-22
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Prac 2013;1:163-71
   PubMed Web of Science ®Google Scholar
• Lloyd A, Turk FL, Canonica GW. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ 2007;10:285-96
   Google Scholar
• Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36
   PubMed Web of Science ®Google Scholar
• Blackwell LS, Marciel KK, Quittner AL. Utilization of patient-reported outcomes as a step towards collaborative medicine. Paed Resp Rev 2013;14:146-51
   Google Scholar
• Hanania NA, Wenzel S, Rosén K Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11
   PubMed Web of Science ®Google Scholar